r-hGH

ApprovedSmall molecule

Merck & Co.

r-hGH is one of 52 small molecule programs targeting Turner syndrome. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Turner SyndromeActive, not recruiting

GrowthActive, not recruiting

Turner SyndromeApproved

Active, not recruiting

GrowthApproved

Active, not recruiting

Competition

Competitive Landscape

364 competitors in Growth

#DrugCompanyPhaseTrials

r-hGH

Merck & Co.

Approved

1 2

Lovenox

Sanofi

Preclinical

2 3

Lenvima

Eisai

Preclinical

1 4

Aricept

Eisai

Preclinical

1 5

Zolymbus

AbbVie

Preclinical

1 6

Zyloprim

Alnylam Pharmaceuticals

Preclinical

1 7

Somavaratan

Novo Nordisk

Preclinical

—8

Accutane

CConrado Roberto Hoffmann Filho

Preclinical

1 9

Glucagon

XXeris Pharmaceuticals

Preclinical

1 10

Prilosec

DDexcel Pharma Technologies Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Turner syndrome1 trial

Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT01066052·115 enrolled

Growth1 trial

A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT01157793·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for r-hGH. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — r-hGH compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for r-hGH. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Merck & Co.

r-hGH

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Turner syndrome1 trial

Growth1 trial

References

Drug Info

Quick Facts

Related News